Sector Expert: Tony Fiorino
Dr. Tony Fiorino brings to BrainStorm Cell Therapeutics extensive experience in both biotechnology financing and drug development. Prior to joining BrainStorm, he was a managing director at Greywall Asset Management, a healthcare equity fund. Previously, Dr. Fiorino was founder, president and CEO of EnzymeRx Inc., where he led the acquisition of a late-stage preclinical biologic, and then development of the compound through Phase 1 and 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRX, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup and Pequot Capital. He earned an MD and a PhD from the Albert Einstein College of Medicine and a bachelor of science degree from the Massachusetts Institute of Technology.
An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis (ALS). Dr. Tony Fiorino, the U.S.-based CEO of BrainStorm Cell Therapeutics Inc., tells The Life Sciences Report how his company is winning over American investors with a revolutionary, university lab-backed cell therapy.